Global and India Short-acting Recombinant Human Erythropoietin Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Short-acting Recombinant Human Erythropoietin Market Report & Forecast 2024-2034
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The global Short-acting Recombinant Human Erythropoietin revenue was US$ 9168 million in 2022 and is forecast to a readjusted size of US$ 13830 million by 2029 with a CAGR of 6.2% during the forecast period (2024-2034).
In India, the Short-acting Recombinant Human Erythropoietin revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Short-acting Recombinant Human Erythropoietin include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Short-acting Recombinant Human Erythropoietin market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Short-acting Recombinant Human Erythropoietin will continue to grow rapidly in the future.
Global Short-acting Recombinant Human Erythropoietin Scope and Market Size
Short-acting Recombinant Human Erythropoietin market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Short-acting Recombinant Human Erythropoietin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Short-acting Recombinant Human Erythropoietin market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Anemia
Kidney Disorders
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Short-acting Recombinant Human Erythropoietin definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Short-acting Recombinant Human Erythropoietin companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Short-acting Recombinant Human Erythropoietin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Short-acting Recombinant Human Erythropoietin sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
The global Short-acting Recombinant Human Erythropoietin revenue was US$ 9168 million in 2022 and is forecast to a readjusted size of US$ 13830 million by 2029 with a CAGR of 6.2% during the forecast period (2024-2034).
In India, the Short-acting Recombinant Human Erythropoietin revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2024-2034).
The global key players of Short-acting Recombinant Human Erythropoietin include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Short-acting Recombinant Human Erythropoietin market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Short-acting Recombinant Human Erythropoietin will continue to grow rapidly in the future.
Global Short-acting Recombinant Human Erythropoietin Scope and Market Size
Short-acting Recombinant Human Erythropoietin market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Short-acting Recombinant Human Erythropoietin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Short-acting Recombinant Human Erythropoietin market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segment by Application
Anemia
Kidney Disorders
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Short-acting Recombinant Human Erythropoietin definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Short-acting Recombinant Human Erythropoietin companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Short-acting Recombinant Human Erythropoietin in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Short-acting Recombinant Human Erythropoietin sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices